Erasca Inc Stock Today
| ERAS Stock | USD 1.44 0.03 2.04% |
PerformanceVery Weak
| Odds Of DistressAbove Average
|
Erasca is selling for under 1.44 as of the 17th of March 2025; that is 2.04 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.42. Erasca has over 57 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of July 2021 | Category Healthcare | Classification Health Care |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers. The company was incorporated in 2018 and is headquartered in San Diego, California. The company has 282.73 M outstanding shares of which 34.52 M shares are currently shorted by private and institutional investors with about 26.53 trading days to cover. More on Erasca Inc
Moving together with Erasca Stock
| 0.84 | ENVB | Enveric Biosciences Earnings Call This Week | PairCorr |
Moving against Erasca Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Erasca Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsErasca can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Erasca's financial leverage. It provides some insight into what part of Erasca's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Erasca Inc (ERAS) is traded on NASDAQ Exchange in USA. It is located in 3115 Merryfield Row, San Diego, CA, United States, 92121 and employs 126 people. Erasca is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 407.13 M. Erasca Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 282.73 M outstanding shares of which 34.52 M shares are currently shorted by private and institutional investors with about 26.53 trading days to cover.
Erasca Inc currently holds about 371.48 M in cash with (101.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Erasca Probability Of Bankruptcy
Ownership AllocationErasca holds a total of 282.73 Million outstanding shares. The majority of Erasca Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Erasca Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Erasca. Please pay attention to any change in the institutional holdings of Erasca Inc as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Erasca Ownership Details
Erasca Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-12-31 | 6.6 M | |
| 5am Venture Management, Llc | 2024-12-31 | 5.4 M | |
| Octagon Capital Advisors Lp | 2024-12-31 | 5.1 M | |
| Geode Capital Management, Llc | 2024-12-31 | 4.6 M | |
| Partner Fund Management Lp | 2024-12-31 | 4.4 M | |
| Citadel Advisors Llc | 2024-12-31 | 4.3 M | |
| Millennium Management Llc | 2024-12-31 | 4.2 M | |
| Woodline Partners Lp | 2024-12-31 | 4.1 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 2.8 M | |
| T. Rowe Price Investment Management,inc. | 2024-12-31 | 16.7 M | |
| Vr Adviser, Llc | 2024-12-31 | 16.2 M |
Erasca Historical Income Statement
Erasca Stock Against Markets
Erasca Corporate Management
| Michael Varney | Scientific Development | Profile | |
| Lisa TesvichBonora | Chief Officer | Profile | |
| Nik Chetwyn | VP Operations | Profile | |
| CPA MS | VP Fin | Profile | |
| Wei MD | Chief Officer | Profile | |
| JD Esq | General Secretary | Profile | |
| Esq JD | General Secretary | Profile |
Additional Tools for Erasca Stock Analysis
When running Erasca's price analysis, check to measure Erasca's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Erasca is operating at the current time. Most of Erasca's value examination focuses on studying past and present price action to predict the probability of Erasca's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Erasca's price. Additionally, you may evaluate how the addition of Erasca to your portfolios can decrease your overall portfolio volatility.